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Abstract
Purpose Garenoxacin, a novel des-F(6)-quinolone, possesses
potentantibacterialactivityagainstinfectiouspathogensinthe
respiratory tract. Population pharmacokinetic/pharmacody-
namic (PK/PD) modeling and Monte Carlo simulations were
used to optimize garenoxacin dosage regimens.
Methods At the end of phase II stage, the clinical dose of
garenoxacin was predicted to be 400 mg once daily by the
interim PK/PD analysis using phase I and phase II clinical
data. The criteria used to determine an optimal dose were (1)
the target attainment of the area under the unbound concen-
tration–time curve divided by the minimum inhibitory
concentration (fAUC0−24/MIC ratio) and (2) the maintenance
of a trough concentration above the mutant prevention
concentration. In a confirmatory phase III study, garenoxacin
was administered 400 mg once daily to 136 patients infected
with mild or moderate chronic respiratory diseases.
Results Logistic regression analysis showed that fAUC0−24/
MIC ratio was a significant variable that predicted clinical
response (p=0.0164). Of all subjects, 92.4% reached the
target value of fAUC0−24/MIC ratio>30 h, and the clinical
efficacy rate of this population was 91.8%. On the other
hand, there was no significant relationship between expo-
sure values (AUC0−24 and maximum concentration) and the
incidence of adverse events by the Mann–Whitney test.
Conclusions The antimicrobial efficacy of the actual phase
III study was consistent with the expectation from the
Monte Carlo PD simulation. We were able to show that the
optimal garenoxacin dosage regimens were successfully
determined using prospective population PK/PD analysis
and clinical trial simulations.
Keywords Garenoxacin.Population pharmacokinetics.
Pharmacodynamics.Monte Carlo simulation.Dose
finding.Model-based drug development
Introduction
Garenoxacin is a novel des-F(6)-quinolone antibacterial
drug that lacks a fluorine substituent at the C-6 position in
the quinolone ring, which had been believed to be
indispensable in past fluoroquinolone antibacterial drugs.
Garenoxacin has a broad spectrum of antibacterial activity
against Gram-positive and Gram-negative aerobic and
anaerobic bacteria, including Chlamydia spp., Mycoplasma
pneumoniae, and Legionella spp. [1, 2]. This drug also
showspotentactivityagainstmultidrug-resistantStreptococcus
pneumoniae [3], β-lactamase-producing Moraxella catarrha-
lis [4], and β-lactamase-nonproducing and ampicillin-
resistant Haemophilus influenzae (BLNAR) [5].
Garenoxacin was approved by the Ministry of Health,
Labour, and Welfare (MHLW) in Japan in 2007 for the
treatment of pneumonia, secondary infection of chronic
respiratory diseases (SICRD), acute bronchitis, sinusitis,
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In the past, dose-finding studies of antimicrobial drugs
were based on the pharmacokinetics (PK) in healthy
volunteers who participated in a phase I study and the
antibacterial activity against clinical isolates, while account-
ing for the dosage regimen of similar classes of drugs. The
validity of the selected candidate dose was subsequently
confirmed in a controlled trial using two or more dose levels.
However, the conventional dose-finding method is still
empirical and lacks a scientific rationale for choosing the
most appropriate dose.
The efficacy of the antimicrobial drugs developed in
recent years is approximately 90% against respiratory tract
infection. Due to these high efficacy rates, it is difficult to
decide upon the optimal dose based upon simple compar-
isons of clinical efficacy and safety profiles at different
doses. For example, in a dose-finding study of telithromycin,
a ketolide antibiotic, the clinical efficacy of 600 mg once
daily and 800 mg once daily against community-acquired
pneumonia (CAP) was 92.9 (39/42) and 95.8% (46/48),
respectively [6]. In a dose-finding study of doripenem, a
carbapenem antibiotic, the clinical efficacy of 250 mg twice
daily (b.i.d.) and 500 mg b.i.d. against SICRD were 100
(36/36) and 88.2% (30/34), respectively [7]. No clear
relationship between clinical efficacy rate and dose can be
observed in such a dose-based clinical trial design.
In terms of the antibacterial action of quinolones, a
number of recent studies have clearly shown that the area
under the concentration–time curve (AUC) divided by the
minimum inhibitory concentration (MIC) (AUC/MIC ratio)
is the most important predictive value of clinical and
microbiological response. Ambrose et al. reported that the
unbound AUC/MIC ratio (fAUC/MIC ratio) was more
predictive of outcome than the total AUC/MIC ratio [8]. As
the efficacyindexforgarenoxacinaswellasotherquinolones,
AUC/MIC ratio was deemed appropriate for use in dose
finding [9]. In Monte Carlo simulation, the target value of
garenoxacin was assumed to be an AUC0−24/MIC ratio of
125 h based on ciprofloxacin data in the report of Forrest et
al. [10]. The serum protein binding of garenoxacin was 75%
[11], and the AUC0−24/MIC ratio of 125 h was almost equal
to the fAUC0−24/MIC ratio of 30 h. This target value was
necessary to eradicate bacteria typical of respiratory tract
infection (S. pneumoniae, Staphylococcus aureus, Klebsiella
pneumoniae, H. influenzae,a n dM. catarrhalis)[ 11, 12].
It has been reported that resistant mutants are selected
exclusively within a concentration range (mutant selection
window) between the mutant prevention concentration
(MPC) and MIC [13, 14]. To restrict resistant mutants, the
optimal dose needs to be selected in view of the
maintenance of a trough concentration above the MPC.
As the MPC of garenoxacin against common bacteria
(S. pneumoniae, S. aureus,a n dH. influenzae)i s< 1μg/ml,
the probability of having a trough concentration >1 μg/ml
was computed at several doses.
Population pharmacokinetics (PK) and PK/PD analysis
are powerful approaches to investigate exposure–response
relationships for both efficacy and safety. Population PK
takes into consideration the inter-individual variability in
PK parameters of the target patient population, and various
infectious bacteria also show various MIC distributions in
clinical isolates. The Monte Carlo pharmacodynamic
simulation is a computing tool that is used to create an in
silico resemblance of the real world and is useful to predict
clinical efficacy for assumed doses and dosage regimens
[15]. In the study reported here, we applied prospective
population PK/PD analysis together with Monte Carlo PD
simulation to find and confirm the optimal dose of
garenoxacin during drug development in Japan. Our
successful experience provides a rational strategy for a
learning–confirming paradigm of drug development with
the benefits of a shorter time period and a fewer number of
trials/patients.
Material and methods
Outline of development strategy
The development of garenoxacin in Japan was achieved by
phase I to phase III clinical trials (1999–2005), and this
drug was approved in July 2007. The detailed protocol and
results of these studies are published elsewhere [16–18].
Briefly, each clinical study was reviewed and approved by
the institutional review board of each participating institu-
tion, and informed consent was obtained from all patients
prior to participation in the specific study. These studies
were conducted in accordance with the guidelines of Good
Clinical Practice established by the International Confer-
ence on Harmonization. The phase I study was conducted
in healthy volunteers at doses varying from 100 to 600 mg.
The phase II study of garenoxacin 200 or 400 mg once
daily for 7–14 days was conducted in patients with
respiratory tract infection (CAP and SICRD). The interim
population PK model was developed using plasma drug
concentration data from subjects who participated in the
phase I and II studies. The Monte Carlo PD simulation was
performed using the interim population PK parameters and
the isolated MIC distribution of the major infectious
bacteria. At this stage, the optimal dose was predicted to
be 400 mg once daily, based upon (1) the target attainment
of the AUC0−24/MIC ratio and (2) the maintenance of a
trough concentration above the MPC. In the subsequent
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acin was givenoncedailyfor 10daystopatientswithSICRD.
The population PK model was revised by adding the phase III
data, and PK/PD analyses for efficacy and safety were
conducted. The optimal recommended dose of 400 mg once
daily was confirmed by comparing the actual results of
efficacy in phase III study and Monte Carlo simulations
(predictions) at the stage just after the phase II study.
PK data
The plasma garenoxacin concentration data used for the
population PK analysis are shown in Table 1 [16–18].
The data from five studies (phase I−III studies conducted
in Japan) were utilized for the PK analysis. In each study,
after blood was drawn, the plasma was separated and
stored at −20°C until measurement. The concentrations of
garenoxacin were measured by an assay of validated
liquid chromatography with tandem mass spectrometry
(LC/MS/MS) using an internal standard [19]. The lower
limit of quantification was 0.01 μg/ml, and values below
this limit were treated as zero for the population PK
analysis. A total of 13 measurements from nine subjects
were <0.01 μg/ml. The Monte Carlo PD simulation used
the interim population PK model developed using 1,396
plasma PK samples (104 subjects) from the phase I and II
studies. The final population PK model was obtained
using 1,742 plasma PK samples (237 subjects) of phase
I−III studies.
Determination of MICs
The MIC distributions of the clinically isolated bacteria
were determined by the standard agar dilution methods of
the Japanese Society of Chemotherapy [20]. The MICs for
samples obtained in the phase III study were determined by
the Clinical and Laboratory Standards Institute (CLSI) [21].
The method of the Japanese Society of Chemotherapy used
different dilution and medium from the CLSI method.
Although the resulting MIC values slightly disagree, these
differences were thought to have little influence on the
present analysis.
Table 1 Sources of plasma garenoxacin concentration data collected in the Japanese clinical studies
Study Subject Dosage and sampling time Number
of subjects
Number
of plasma
samples
a
Reference
Phase I: single dose Healthy volunteers Single-dose administration in a fasted condition. 24 382 [18]
100, 200, 400, 600 mg
Standard PK sampling (16 time points/individual)
(0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24,
36, 48, 72 h)
Phase I: multiple dose Healthy volunteers Multiple dose administration in a fasted condition. 11 502 [18]
200, 400 mg once daily for 7–14 days
Standard PK sampling (42 or 49 time points/individual)
(0.25, 0.5, 0.75, 1, 1.5, 2, 3,
4, 6, 8, 12, 24, 48, 72 h)
Phase I: food effect Healthy volunteers Single dose administration in fasted or fed condition. 14 437 [18]
400 mg
Standard PK sampling (32 time points/individual)
(0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24,
36, 48, 72 h)
Phase II
b Patients Multiple dose administration 55 75 [16]
200 or 400 mg once daily for 7–14 days
Sparse sampling (trough and optional one point/individual)
Phase III
c Patients Multiple-dose administration 133 346 [17]
400 mg once daily for 10 days
Sparse sampling [two or four points (trough and
peak)/individual]
Total 237 1,742
aThe number of concentrations above the lower limit of quantification (0.01 μg/ml).
bTwo blood samples per individual were collected in 20 patients (36.4%), and one sample was collected in each of 35 patients (63.6%).
cThe number of blood collection points for each patient was four or more in 25 patients (18.8%), three in 33 patients (24.8%), two in 72 patients
(54.1%), and one in 3 patients (2.3%).
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The population PK parameters and the objective function
value (OBJ) were estimated using NONMEM software
[22]. The first-order method in NONMEM version V, level
1.0 was used for both the end of phase II and phase III
studies as it was the latest version at the time of decision-
making in 2002. Each subject's parameter was calculated by
the Bayesian method using the POSTHOC option. Since
the first-order method has the limitation that it only yields
reasonable results when the between-subject variability is
small, we re-estimated the parameters of the final model
using the first-order conditional estimation method with
interaction by NONMEM version VI, level 2.0.
Structural model development A linear one-compartment
openmodelwithfirst-orderabsorptionwasusedasastructural
model since the residualerror versus time plot was detected as
deformation when using the two-compartment model. The
parameters of total body clearance (CL/F), distribution
volume (V/F), and first-order absorption rate constant (ka)
were estimated by using the PREDPP subroutines (ADVAN2
and TRANS2) of the NONMEM program.
Statistical model The intra-individual (residual) variability
was described by a constant coefficient of variation (CV)
error model (Eq. 1).
Cij ¼ Cpredij   1 þ "ij

ð1Þ
where Cij is the measured plasma concentration value of the
j-th subject at i-th time, Cpredij is the predicted plasma
concentration value of the j-th subject at i-th time, and εij is
a random variable with a mean of zero and a variance of σ
2.
The inter-individual variability for the PK parameter was
assumed by a log-normal distribution (Eq. 2).
Pj ¼ P   exp hj

ð2Þ
where Pj is parameter value of the j-th subject, P is the
estimated population mean, and ηj is a random variable
with a mean of zero and a variance of 5
2.
Covariate model Typical functional forms used for cova-
riate analysis included linear, power, and additive shift of
these forms (eqs. 3, 4 and 5).
Linear : Xj ¼ qx
int þ qx
cov  ð covj   covÞð 3Þ
Power : Xj ¼ qx
int   covj=cov
 qxcov ð4Þ
Additive shift : Xj ¼ qx
int þ qx
cov   covj covj ¼ 1or0

ð5Þ
where Xj is the estimated typical parameter value in the j-th
subject, covj is the measured value of a particular covariate
in the j-th subject, cov is the arithmetic mean value of the
covariate in the population, and θx
int and θx
cov are estimates
of the population mean.
The covariates were searched by forward selection and
confirmed in the final model by the backward elimination.
The model selection was conducted based on visual
inspection of the scatter plot of individual PK parameters
versus covariate values and the likelihood ratio test (α=
0.05). The demographic characteristics examined were age,
gender, body weight (BW), ideal body weight (IBW), and
degree of obesity (obese patient: BW/IBW>1.3) [11]. The
laboratory data examined were those of total bilirubin,
alkaline phosphatase, aspartate aminotransferase, alanine
aminotransferase, and creatinine clearance (CLCR). Creati-
nine clearance was calculated by the Cockcroft–Gault
equation [23]. Since no effect of food on CL/F or ka was
detected in the phase I food effect study [18], the effect of
food was excluded from the covariate analysis.
Assessment of model uncertainty The final model examined
stability and robustness using the bootstrap method [24].
One thousand non-stratified bootstrap datasets of garenox-
acin were generated using plasma samples from the five
studies (phase I−III studies). The parameters were estimated
using the final model for these datasets. The median and 5–
95% percentile was calculated for 1,000 sets of these
parameters and compared with the parameters calculated
from the original dataset. When the parameter values of
both datasets nearly corresponded, the robustness of the
model was confirmed.
Monte Carlo simulation
The MIC distributions of clinical isolates collected from 1994
to 1997 in Japan were used for the Monte Carlo simulation
analysis(Table2) because these were the only available MIC
data at the time of the simulation. The major species of
pathogens were selected from drug-susceptible and drug-
resistant bacteria commonly found in community-acquired
respiratory tract infections. In addition, the garenoxacin MIC
distributions of clinical isolates collected during 1994–1997
[2] were almost similar to those collected during 2000–2005
(during the present clinical trials) [5]; therefore, these data
were considered suitable for the simulation.
The population PK model parameters obtained in the
interim analysis at the end of phase II stage were used for
simulation, and the population PK model equation ofModel 2
(Table 3) was used. The virtual PK/PD data for 10,000 cases
were generated by SAS software (ver. 8.2; SAS Institute,
Cary, NC). The distribution of AUC0−24 in the steady state
42 Eur J Clin Pharmacol (2012) 68:39–53was calculated by Model 2, including CLCR, in which CLCR
determined by the Cockcroft–Gault equation was randomly
sampled from the observed distribution of the patients’ real
values in the phase II study (Table 2;3 4 . 4 −133.2 ml/min,
n=55). The target value of 30 h for the fAUC0−24/MIC
ratio was assumed for S. pneumoniae, S. aureus, K. pneumo-
niae, H. influenzae,a n dM. catarrhalis, which are the major
pathogens of community-acquired respiratory tract infection
[11, 12].
The probability of a trough concentration above the
target value of MPC (1 μg/ml) at various doses was
calculated using Model 2 including CLCR, and the virtual
data for 1,000 cases were generated by SAS software (ver.
8.2). The MPCs against S. pneumoniae (penicillin-sensitive,
-intermediately sensitive, and highly resistant strains of S.
pneumoniae [PSSP, PISP, and PRSP, respectively)], cipro-
floxacin (CIP)-susceptible MSSA, and H. influenzae have
been reported to be <1 μg/ml [5, 25, 26].
Phase III study (PK/PD study)
Japanese patients diagnosed with mild or moderate SICRD
[acute exacerbation of chronic bronchitis (AECB), diffuse
panbronchiolitis, bronchiectasis, emphysema and pulmonary
fibrosis, bronchial asthma, and old pulmonary tuberculosis]
weretargeted[17]. For this study, outpatients or inpatients who
were 18 years of age or older were eligible. For participation in
the study, patients had to demonstrate the following four
conditions: production of purulent or mucopurulent sputum;
increased level of C-reactive protein (CRP; ≥0.7 mg/dl); fever
Table 2 Subject characteristics in the population pharmacokinetic analysis
Characteristics Clinical isolates from Japanese patients End of phase II stage
(interim analysis)
Phase III data
Disease
a – CAP, SICRD SICRD
Number of subjects (n) – 104 133
Healthy subjects/Infected patients (n) – 49/55 –
Males/females (n) – 77/27 87/46
Mean±SD (Min–Max) Mean±SD (Min–Max)
Age (year) – 40.0±20.4 (20–74) 66.3±14.8 (19–94)
Body weight (kg) – 58.5±10.4 (34–83) 52.7±13.0 (33–120)
CLCR (ml/min)
b – 102.4±29.7 (34.4–178.7) 71.1±29.4 (19.3–199.2)
Pathogens MIC90 (Min–Max) [n]
c MIC range [n]
d MIC range [n]
e
Methicillin-sensitive Staphylococcus
aureus (MSSA)
0.025 (0.0125–0.05) [23] ≤0.025 [2] ≤0.06–0.25 [8]
Penicillin-sensitive strains of Streptococcus
pneumoniae (PSSP)
0.05 (0.025–0.05) [24] 0.10 [3] ≤0.06–0.25 [6]
Penicillin intermediately or highly resistant
strains of S. pneumoniae (PISP/PRSP)
0.05 (0.025–0.05) [23] 0.05 [1] ≤0.06 [8]
Haemophilus influenzae 0.0125 (0.00313–0.0125) [50] ≤0.025 [10] ≤0.06–0.5 [29]
Moraxella catarrhalis 0.10 (≤ 0.00625–0.39) [50] ≤0.025 [1] ≤0.06 [7]
Klebsiella pneumoniae 3.13 (0.05–25) [54] – 0.12–0.5 [4]
Pseudomonas aeruginosa > 100 (0.78–>100) [35] 0.20–0.78 [2] 0.12–32 [5]
Streptococcus pyogenes –– 0.05 [1]
Haemophilus parainfluenzae –– 0.20–3.13 [2]
Stenotrophomonas maltophilia –– 0.39 [1]
aCAP, Community-acquired pneumonia; SICRD, secondary infection of chronic respiratory diseases
bCreatinine clearance (CLCR) was calculated by the Cockcroft-Gault equation. Male: CLCR (ml/min)=([140 – age (years)]× WT (weight, kg)/[72×
serum creatinine (SCr, mg/dl)]. Female: CLCR (ml/min)=([140 – age (years)]×WT (kg)/[72×SCr (mg/dl)]× 0.85
cThe pathogens were clinically isolated from Japanese patients during 1994–1997. The minimum inhibitory concentration (MIC) required to
inhibit the growth of 90% of organisms (MIC90) was determined by standard agar methods of the Japan Society of Chemotherapy. Other
pathogens were: ciprofloxacin (CIP)-susceptible methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 0.025 (0.0125–0.05) (n = 51),
CIP-resistant MRSA 6.25 (0.10–6.25) (n = 26), vancomycin-resistant enterococci (VRE) 3.13 (≤ 0.05–3.13) (n = 24)
dThe pathogens were isolated from 26 patients of the phase II study. The MICs were determined by standard agar methods of the Japan Society of
Chemotherapy. Other pathogens were: S. intermedius with a MIC of 0.05 (n = 1), S. constellatus 0.10 (n = 1), K. oxytoca 0.05, 0.10 (n = 2), M.
pneumoniae 0.015 (n = 2), and K. pneumoniae whose MIC was not measured (n =1 )
eThe pathogens were isolated from 66 patients who participated in the pharmacokinetic/pharmacodynamics (PK/PD) analysis of the phase III
study. The MICs were determined by the Clinical and Laboratory Standards Institute (CLSI)
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3). Patients were also
required to meet at least two of the following criteria:
increased cough, dyspnea, or an increase in sputum volume.
In this study, 400 mg of garenoxacin was administered once
daily for 10 days. The clinical efficacy was evaluated 7–
14 days after the initiation of treatment. The blood collection
points and timing were set by examining the capability of the
parameter estimation using simulated drug concentration data.
The blood collection schedule assumed the following four
cases: Case 1 included four points with two peaks and two
troughs; Case 2 included two points with one peak and one
trough; Case 3 included three points with two peaks and one
trough; Case 4 included two points with two troughs.
Individual estimation of both CL/F and V/F was possible for
Cases 1–3, but not for Case 4. Therefore, the blood collection
schedule in the phase III study was designed to include two to
four points per individual with peaks and troughs.
PK/PD analysis in the phase III study
PK/PD analysis of efficacy The AUC0−24 was calculated
for each patient using the final population PK model. The
measured MIC and AUC0−24 from patients in whom the
infecting organism had been detected were used to calculate
the fAUC0−24/MIC ratio for these patients. When two or
more infecting bacteria were detected in a patient, the
higher MIC was used. It is noted that the fAUC0−24/MIC
ratio is widely used as a no-dimension parameter in the
field of antimicrobial agents [27]. This article attaches the
unit of time (h) since the units of fAUC0−24 are mass/
volume × time, and the units of MIC are mass/volume;
therefore, the unit of the fAUC0−24/MIC ratio is time (h).
The relationship between fAUC0−24/MIC ratio and clinical
response was analyzed by logistic regression analysis. For
the analysis of probability of cure, the logistic regression
model was used with the fAUC0−24/MIC ratio, in which
cure and failure were coded as 1 and 0, respectively. The
fAUC0−24/MIC ratio was also divided into a categorical
variable by the upper or lower limit of the target value. The
values were explored using classification and regression
tree (CART) analysis with SPSS software (ver. 14).
PK/Safety analysis The relation between drug exposure
values [AUC0−24 or peak concentration Cmax)] and the
incidence of adverse events was analyzed. The adverse
events during the study were assessed on the basis of all
accompanying symptoms and laboratory test data. The
patients were divided into two groups on the basis of
whether an adverse event occurred, and the drug exposure
values (AUC0−24 and Cmax) distributions of each group
were calculated. The Mann–Whitney test was applied to
assess any relationship between drug exposure values and
incidences of adverse events. The level of two-tailed
significance in the verification was set at 5%.
Results
Plasma samples
The population PK analysis reported here used the plasma
concentration data obtained from five clinical studies
Table 3 Development of population PK model for garenoxacin
Model no. Model construction
a CV 5CL/F
2 CV 5Vd/F
2 OBJ (p value)
End of phase II stage (interim analysis)
b
1 Base model 19.4% 18.3% 356.754
2 CL/F= θ1+ θ2×(CLCR−85) 20.6% 21.0% 271.509 (p <0.001)
End of phase III stage (final analysis)
c
1 Base model 37.4% 37.0% 1475.267
2 CL/F= θ1+ θ2×(CLCR−85) 19.5% 32.4% 1403.379 (p<0.001)
V/F= θ3
3 CL/F= θ1+ θ2×(CLCR−85) 20.6% 16.4% 1309.516 (p<0.001)
V/F= θ3×(WT/55)
θ4
4 CL/F= θ1+ θ2×(CLCR−85) 20.6% 16.4% 1298.040 (p<0.001)
V/F= θ3×(WT/55)
θ4+ θ5×GEN
5 (final model) CL/F= θ1+ θ2×(CLCR−85)+ θ3×(WT−55) 20.1% 15.8% 1292.110 (p =0.015)
V/F= θ4×(WT/55)
θ5+ θ6×GEN
CV, Coefficient of variance; OBJ, objective function value
aCL/F, Total body clearance; V/F, distribution volume/F; GEN, gender (1: male; 0: female); θ, population mean parameters
bFirst-order method (NONMEM version V, level 1.0)
cFirst-order conditional estimation method with interaction (NONMEM version VI, level 2.0)
44 Eur J Clin Pharmacol (2012) 68:39–53(phase I−III studies) conducted in Japan (Table 1). No data
were excluded as outliers. The plasma garenoxacin con-
centration–time profile and visual predictive check by the
final model is shown in Fig. 1. The plot of median values
locates to the center of distribution of the data points; Fig. 1
also plots the area between the 5th and 95th percentiles of
simulated data prediction, an area which is similar to that
created by the 5th to 95th percentiles of the real data. The
5th percentile of the observed values from healthy
volunteers (left panel) was slightly higher than the
simulated data using the final model, probably due to the
smaller variability. It is noted that the data from phase II
(open circles) corresponded to the 200 mg and 400 mg
doses, which give the impression that these data show a
lower distribution when compared with those of phase III
(400 mg dose only). There was no pronounced difference in
the distributions of observed values for the 400 mg dose
between phase II and phase III studies, and the population
characteristics were similar, with the exception of a wider
individual variability in age in the phase III study.
Phase I studies were conducted as three studies; a total of
1,321 plasma samples were collected from 49 subjects. For
the phase II study, 62 patients with respiratory tract
infection participated (36 with CAP and 26 with SICRD).
A total of 41 plasma samples were obtained from 28
patients receiving 200 mg garenoxacin once daily, and 34
plasma samples were obtained from 27 patients receiving
400 mg garenoxacin once daily. For the phase III study, the
346 plasma garenoxacin concentrations were obtained from
133 of 136 patients with SICRD.
Subject characteristics
The characteristics of the subjects who participated in the
population PK analysis are shown in Table 2. Interim
population PK analysis was performed on data from 55
patients and 49 healthy volunteers. The final analysis of the
phase III data addition covered 188 patients and 49 healthy
volunteers. The patient characteristics from only the phase
II study (shown as mean±standard deviation) were: age,
55.4 ±16.6 years; body weight, 54.9±11.2 kg; CLCR, 84.6±
24.8 ml/min. Their characteristics were similar to those in
the phase III study. These studies involved CAP and
SICRD because they are respiratory tract infections targeted
by quinolone.
Development of the population PK model
The process for reaching the final model is shown in Table 3.
A linear one-compartment open model with first-order
absorption was conducted as the base model (Model 1). In
the first covariate examination, a linear relationship was
observed between CLCR and CL/F (Model 2). Model 2 was
selected as the interim population PK model and then used
for the Monte Carlo simulations. Other covariates were
investigated further in the final analysis. A power relation-
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Fig. 1 Plasma garenoxacin concentration versus time profile. Plotted
symbols show the observed concentration data, and the lines show the
results of visual predictive checks. For simulated data, the 5th, 50th,
and 95th percentiles (from bottom to top) of the final model simulated
data are displayed; for real data, the 5th, 50th, and 95th percentiles
(from bottom to top) of the observed concentrations are displayed.
These percentiles were set for the 400 mg dose, which is clinical
standard dose
Eur J Clin Pharmacol (2012) 68:39–53 45ship was obtained between body weight and V/F (Model 3).
Moreover, an additive shift was found between gender and
V/F (Model 4). Also, a linear relationship was shown
between body weight and CL/F (Model 5). Model 5 was
selected as the final population PK model.
Population PK parameters of the final model
Table 4 shows the population PK interim and final models.
The parameter estimates of the interim Model 2 and the final
model showed similar values. In the final model, the same
covariates were selected for both the first-order method of
NONMEM ver. V (not displayed) and the first-order condi-
tional estimation method with the interaction of NONMEM
ver. VI. The model was validated through the visual predictive
check method (Fig. 1). Diagnostic plots showed a slight
discrepancy between the observed values and the population
mean predictions, but the prediction was improved for
individual estimates by the Bayesian method (Electronic
Supplementary MaterialFig.1).Thesecorrelationcoefficients
(r value) were 0.831 for populations and 0.896 for
individuals. The final PK parameters were well estimated
with small standard errors. Estimates of the shrinkage for
CL/F, V/F, and ka were 0.226, 0.295 and 0.573, respectively,
suggesting that the individual estimates for CL/F and V/F
were reasonably robust and that the individual estimates of
ka were subjected to shrinkage and therefore less reliable.
The uncertainty of the parameters was assessed by a non-
stratified bootstrap method with 1,000 replications. The
NONMEM software program was performed using the
simulated data and repeating the simulation by the bootstrap
re-sampling 1,000 times. All 1,000 estimation replications
converged successfully. The average values of the estimated
parameters by the bootstrap method resembled the final
estimates of the population PK parameters (Table 4).
Influence of the covariate on AUC0−24 and Cmax
The influence of the covariates (renal function, body weight)
onAUC0−24 and Cmax are shown in Fig. 2. In the relationship
between CLCR (renal function) and AUC0−24,w h e nC L CR
values were normal (80–110 ml/min) or showed mild renal
impairment (50–79 ml/min) or moderate renal impairment
(20–49 ml/min), the corresponding AUC0−24 values were
Table 4 Final population pharmacokinetics parameters for garenoxacin
Parameter End of phase II stage
a End of phase III stage
b Bootstrap (n =1,000)
c
Model 2 Final model
CL/F (ml/min) CL/F=θ1+θ2×(CLCR−102) CL/F= θ1+ θ2×(CLCR−85)+ θ3×(WT− 55)
θ1 66.7±1.7 64.3±1.25 65.3 (62.2–76.3)
θ2 0.167±0.036 0.213±0.0309 0.184 (0.109–0.261)
θ3 − 0.276±0.113 0.328 (0.090–0.540)
V/F (l) V/F=θ4 V/F=θ4× (WT/55)
θ5+ θ6×GEN
θ4 61.8±1.7 53.9±1.89 55.4 (49.8–68.4)
θ5 − 0.739±0.104 0.502 (0.195–0.873)
θ6 − 6.98±1.88 8.02 (3.85–10.56)
ka (1/h) 4.72±0.54 2.14±0.223 2.16 (1.69–2.99)
Coefficent of variance Coefficient of variance
Inter-individual variability Inter-individual variability
5CL/F
2 0.0424±0.0097 20.6% 0.0403±0.00748 20.1% 0.0374 (0.0149–0.0673)
5V/F
2 0.0443±0.0132 21.0% 0.0249±0.00585 15.8% 0.156 (0.0181–0.3915)
5CL/F,V/F 0.0330±0.0115 0.0292±0.00618 0.0096 (0.0036–0.0385)
(r
d=0.761) (r=0.922)
5ka
2 2.63±0.56 162% 0.411±0.0863 64.1% 0.470 (0.269–1.073)
Intra-individual variability Intra-individual variability
σ
2 0.0645±0.0057 25.4% 0.105±0.0060 32.4% 0.113 (0.095–0.162)
ka, First-order absorption rate constant
aFirst-order method (NONMEM version V, level 1.0). Data are presented as the estimated value ± standard error
bFirst-order conditional estimation method with interaction (NONMEM version VI, level 2.0). Data are presented as the estimated value ±
standard error
cData presented as median, with the 5−95% percentiles in parenthesis
dr, Correlation coefficient
46 Eur J Clin Pharmacol (2012) 68:39–5396–105, 105–117 and 117–132 μg·h/ml, respectively. A
negative relation was seen for CLCR and AUC0−24.W h e n
there was a moderate impairment of renal function, the
AUC0−24 increased by about 1.3-fold compared to normal
function. An inverse relation was found between CLCR and
Cmax.T h eC max increased about 1.1-fold when the CLCR
indicated moderate renal impairment. In a comparison by
body weight between a 100-kg patient and 60-kg patient, the
AUC0−24 and Cmax decreased by 0.86-fold, showing an
inverse relation between the parameters and body weight.
Prediction of clinical efficacy by Monte Carlo simulation
The infecting bacteria isolated from patients with CAP in
Japan mainly consisted of S. aureus [methicillin-sensitive
and methicillin-resistant S. aureus (MSSA, MRSA, respec-
tively)], S. pneumoniae (PSSP, PISP, and PRSP), H.
influenzae, M. catarrhalis, and K. pneumoniae [28]. The
probability for the fAUC0−24/MIC ratio of each infecting
organism to exceed 30 h (estimated by Monte Carlo
simulation) is shown in Fig. 3. With a dose of ≥100 mg, the
probability of 100% attainment could be expected for MSSA,
CIP-susceptible MRSA, PSSP, PISP, PRSP, H. influenzae,a n d
M. catarrhalis. With a dose of 100 or 200 mg, the probability
of 75−80% attainment could be expected for K. pneumoniae,
while the attainment probability reached a plateau (90%)
at ≥400 mg. For vancomycin-resistant enterococci (VRE),
CIP-resistant MRSA, and P. aeruginosa, the probability of
target attainment was only 10−30% at 400 and 600 mg.
The probability for a trough garenoxacin concentration
above the MPC (1 μg/ml) against S. aureus, S. pneumoniae,
and H. influenzae i ss h o w ni nF i g .4. The plasma concentra-
tion was expected to exceed the MPC during the 400 mg
treatment. The probability at 300 mg on Day 1 was 81.4%,
AUC0-24 and renal function (CLCR)
Normal renal function
CL     = 80 – 110 ml/min
Mild deficiency
CL     = 50 – 79 ml/min
Moderate deficiency
CL     = 20 – 49 ml/min
AUC0-24 and body weight
40 60 80 100 120 140 160
AUC0-24 (µg￿h/ml)
80 – 100 kg
60 – 79 kg
40 – 59 kg              
Population mean
104 µg￿h/ml
CR
CR
CR
Cmax and renal function (CLCR)
Normal renal function
CL      = 80 – 110 ml/min
Mild deficiency
CL      = 50 – 79 ml/min
Moderate deficiency
CL      = 20 – 49 ml/min
Cmax and body weight
468 1 0 1 2
Cmax (µg/ml)
80 – 100 kg
60 – 79 kg
40 – 59 kg              
Population mean
7.75 µg/ml
CR
CR
CR
Fig. 2 Influence of the covari-
ates (renal function and body
weight) on the plasma concen-
tration–time curve from 0 to
24 h (AUC0−24) and peak plas-
ma concentration (Cmax). Expo-
sure values (AUC0−24 and Cmax)
were simulated by the popula-
tion mean parameters of the
final model using the character-
istics of 237 subjects. The
simulation was made by varying
one covariate within the partic-
ular range while all other
covariates were kept at their
mean value. CLCR Creatinine
clearance
Eur J Clin Pharmacol (2012) 68:39–53 47but increased to 100% on Days 5 and 10. The 200 mg dose
was insufficient to exceed the MPC. Therefore, a dose of
400 mg once daily was regarded as an optimal clinical dose
for the phase III study from two Monte Carlo simulations.
Summary of the phase III study population
The plasma garenoxacin concentrations from 133 of 136
patients were used for population PK and PK/safety
analyses. The 66 patients with isolated causative organism
of SICRD and its respective MIC value were used for PK/
PD analysis of the efficacy. Of the 133 patients, 87 patients
were men (65.4%), the mean age was 66.3 years (range 19–
94 years), and the mean body weight was 52.7 kg (range
33–120 kg). The clinical observation for the efficacy was
83.7% (103/123) [17], and the clinical efficacy rate in the
PK/PD analysis population was 87.9% (58/66). The
incidence rate of all adverse events, including abnormal
changes in laboratory test results, was 62.5% (85/136).
PK/PD analysis for efficacy
TheefficacypredictedbythefAUC0−24/MIC ratio in the phase
III study is shown in Table 5. Of all subjects, 92.4% (61/66)
reached the target value of an fAUC0−24/MIC ratio>30 h, and
the clinical efficacy rate of this population was 91.8% (56/61).
The logistic regression analyses of the fAUC0−24/MIC ratio
a n de f f i c a c ya r es h o w ni nT a b l e6 and Fig. 5. The analysis
demonstrated that the fAUC0−24/MIC ratio was a significant
factor affecting clinical response (p=0.0164), and a sigmoid
response curve was seen between the efficacy probabilities
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Fig. 4 Monte Carlo simulation for reaching target mutant prevention
concentration (MPC;1μg/ml) with various doses. Trough concentra-
tion was calculated using the interim population pharmacokinetics
parameters of Model 2 in Table 3 and patient covariates randomly re-
sampled from real CLCR values (34.4–133.2 ml/min, n=55). Trough
concentration was simulated for 1,000 putative cases, and the
probability of reaching above MPC was calculated for various
garenoxacin dosing regimens (doses of 100, 200, 250, 300, 350,
400, and 600 mg). The typical MPC value was <1 μg/ml for S. aureus,
S. pneumoniae,a n dH. influenzae, including resistant strains
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Fig. 3 Monte Carlo simulation for reaching the target attainment
[unbound AUC/minimum inhibitory concentration ratio (fAUC0−24/
MIC)>30 h] with various doses. Steady-state AUC0−24 was calculated
using the interim population pharmacokinetics parameters of Model 2 in
Table 3. The creatinine clearance was randomly simulated from the
observed distribution of the patients real values (34.4−133.2 ml/min, n=
55). The AUC0−24 and MIC values were simulated for 10,000 putative
cases to generate the fAUC0−24/MIC distribution for each pathogen.
MSSA, MRSA Methicillin-sensitive and methicillin-resistant Staphylo-
coccus aureus, PSSP, PISP, PRSP penicillin-sensitive, intermediately
resistant, and highly resistance, respectively, strains of Streptococcus
pneumoniae, VRE vancomycin-resistant enterococci, CIP ciprofloxacin
48 Eur J Clin Pharmacol (2012) 68:39–53and log fAUC0−24/MIC ratio. In addition, the target value for
fAUC0−24/MIC was determined by CART analysis, and an
fAUC0−24/MIC ratio>28 h was found to be a statistically
significant (p=0.0059) predictor of clinical success.
PK/PD analysis for safety
A relation between drug exposure values and the incidence
rate of adverse events was examined by the Mann–Whitney
test(Fig.6). No statistically significant difference in AUC0-24
and Cmax was found between the adverse event and non-
adverse event groups.
Comparison of Monte Carlo simulation and the phase III
study results
The probability for attainment of the target fAUC0−24/MIC
ratio estimated by Monte Carlo simulation was consistent
with the actual efficacy of the phase III study for each strain
(Table 7).
Discussion
During the development of antibacterial drugs, it is
necessary to consider various factors, such as antibacterial
activity, pharmacokinetics, clinical efficacy, patient charac-
teristics, safety, and the prevention of the emergence of
bacterial resistance, among other, when setting the clinical
dose [29, 30]. Previously, an optimal dose of antimicrobial
agents was determined based on clinical trials using
randomization and double-blind studies at various doses.
However, using such study designs, it was difficult to
obtain a dose–efficacy correlation in most cases and,
subsequently, to find the optimal dose for clinical efficacy.
Efficacy of quinolones generally shows a correlation with
the AUC/MIC ratio, and the efficacy of garenoxacin also
showed a strong correlation with the AUC0−24/MIC ratio in
the preclinical study [12]. Therefore, we determined the
optimal dose using the following strategy (1) The AUC0−24/
MIC ratio would be the most relevant PD measurement for in
vivo efficacy; (2) Monte Carlo simulations with the popula-
tion PK parameters combining the MIC distribution and MPC
of the most common infecting bacteria were used to predict a
recommended dose through the probability of target attain-
ment; (3) the validity of an estimated recommended dose by
Monte Carlo simulation was confirmed by PK/PD results in
actual phase III study for respiratory tract infection.
When the Monte Carlo simulation is applied to predict
an optimal dose of fluoroquinolones, the target value of
AUC0−24/MIC ratio against causative bacteria is important
as a surrogate indicator of clinical and microbiological
effectiveness. At first, the target value of garenoxacin was
assumed to be an AUC/MIC ratio of 125 h. The fAUC0−24/
MIC ratio is known to be a better predictor than the total
AUC0−24/MIC ratio [8, 12]. The serum protein binding of
garenoxacin is 75% [11], and the AUC0−24/MIC ratio of
125 h is almost equal to the fAUC0−24/MIC ratio of 30 h.
Andes et al. reported that in a mouse infection model using
garenoxacin, the mean±standard deviation of fAUC0−24/
MIC for S. pneumoniae was 32.5±18 h and that for the
most common causative bacteria (including S. aureus, K.
pneumonia) was 33.2±30 h [12]. Moreover, in an analysis
of clinical trials targeting mild–moderate CAP, acute
exacerbation of chronic bronchitis and sinusitis, Van Wart
Table 6 Results of logistic regression analysis of fAUC0-24/MIC affecting the probability of clinical cure by garenoxacin (n=66, phase III data)
Variable Coefficient (β) Standard error Wald #
2 p value Odds ratio
Logistic regression analysis by continuous value
a
Intercept −0.4565 1.0317 −− −
fAUC0−24/MIC 1.0865 0.4526 5.76 0.0164 2.964
Logistic regression analysis by categorical value
b
Intercept −0.4055 0.9129 −− −
fAUC0−24/MIC>28 h 2.8214 1.0253 7.57 0.0059 16.80
fAUC0−24/MIC>28 h and fAUC0−24/MIC≤28 h were coded as 1 and 0, respectively
aThis value was transformed (common logarithmic transformation)
bVariable was categorized by CART-derived breakpoint
Table 5 Clinical efficacy rates stratified by fAUC0−24/MIC obtained
at the phase III study
fAUC0−24/MIC
(h)
Efficacy rate
(cure/number of patients)
95% confidence interval
for efficacy rate
>30 91.8% (56/61) 81.9 –97.3%
≤30 40.0% (2/5) 5.3–85.3%
>28
a 91.8% (56/61) 81.9–97.3%
≤28 40.0% (2/5) 5.3–85.3%
fAUC0−24/MIC, Unbound AUC/minimum inhibitory concentration ratio
aClassification and regression tree (CART)-derived split
Eur J Clin Pharmacol (2012) 68:39–53 49et al. [11] reported that a garenoxacin dosing target of
fAUC0−24/MIC>30 h was necessary to eradicate typical
bacteria of respiratory infections (H. influenzae, H. para-
influenzae, and M. catarrhalis). From these results, when
targeting the mild–moderate respiratory infections, it seemed
appropriate to set a target value of fAUC0−24/MIC>30 h
(equivalent to AUC0−24/MIC>125 h) for the bacteria of
respiratory tract infection. Therefore, in our analysis, the
target fAUC0−24/MIC ratio was assumed to be 30 h for both
Gram-positive and Gram-negative bacteria. However, it has
been reported that a fAUC0−24/MIC ratio of 70–90 h is
required for Gram-negative bacteria, which is higher than
the target for Gram-positive bacteria [8]. This may be
another reason for conducting the Monte Carlo simulation.
As a result of the actual PK/PD analysis in the phase III
study, logistic regression analysis showed that the fAUC0−24/
MIC ratio was a significant variable associated with clinical
response (Fig. 5). The split value of fAUC0−24/MIC=28 h
was identified by CART analysis. This split value is similar
to the target value of fAUC0−24/MIC=30 h and, therefore,
the validity of a target value of 30 h was confirmed by this
analysis (Table 6; Fig. 5).
The optimal dose was predicted by Monte Carlo
simulation at the end of a phase II study using the interim
population PK model. The model was constructed using
data from phase I studies of healthy volunteers and phase II
studies of infected patients (Table 3). Since no significant
difference in population means and inter-individual vari-
ability of clearance was observed between healthy volun-
teers and patient groups, the model was developed by
pooling data from 55 patients and 49 healthy volunteers.
The optimal dose of garenoxacin was considered from
two viewpoints by two Monte Carlo simulations. One is the
relationship between dose and efficacy predicted within a
dose range from 100 to 800 mg (Fig. 3). The clinical effect
was assumed to be associated with the probability of
attaining a fAUC0−24/MIC of 30 h. Garenoxacin was
expected to possess antimicrobial activity against MSSA,
PSSP, H. influenzae, M. catarrhalis, K. pneumoniae, and
resistant bacteria of CIP-susceptible MRSA, PISP, and
PRSP. On the other hand, garenoxacin was not expected
to be effective against P. aeruginosa and VRE.
The other viewpoint was that the MPC concept combined
with PK profiles could be useful for optimizing the dosing
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50 Eur J Clin Pharmacol (2012) 68:39–53regimen to prevent the emergence of resistant mutants [31].
Attainment of a plasma concentration above the MPC was
considered to be essential when determining the dose
necessary to prevent the emergence of resistance. The MPC
of garenoxacin was 0.5 μg/ml for S. pneumoniae,0 . 4μg/ml
for S. aureus, and 0.06 μg/ml for H. influenzae [25, 26, 32]
and, therefore, was considered to be <1 μg/ml against the
common bacteria. The probability of a trough concentration
>1 μg/ml was computed at several doses. The trough
concentration of the 400 mg dose exceeded 1 μg/ml from
Day 1 (Fig. 4). Homma et al., under conditions using the
time–concentration curves observed by oral administration of
moxifloxacin (400 or 80 mg, once a day) or levofloxacin
(200 mg, twice a day) and with an in vitro PD model, reported
that the levofloxacin- and moxifloxacin-resistant S. pneumo-
niae mutants did not emerge when the fAUC0−24/MPC was
≥13.4 h and unbound peak concentration (fCmax)/MPC was
≥1.20 [33]. In our study, the Cmax of garenoxacin given at a
dose of 400 mg was 7−8 μg/ml, which was much higher than
the MPC against S. pneumoniae (0.5 μg/ml). From these
values, we calculated the fCmax/MPC of garenoxacin to be
3.5–4. In addition, the fA U C / M P Cw a sc a l c u l a t e dt ob e5 2h
from the population mean AUC of 104 μg·h/ml, suggesting
that resistant bacteria are not likely to emerge. The MPC of
garenoxacin was five- to tenfold larger than that of the MIC90.
Consequently, the 400 mg dose was expected to be effective
against common bacteria of respiratory tract infections, as well
as to prevent the emergence of resistance.
Tam et al. [34]r e p o r t e dafAUC/MIC target of 190 h
for the suppression of resistance by garenoxacin treatment
against P. aeruginosa.A ss h o w ni nT a b l e7,t h i st a r g e t
value was achievable for MSSA, PSSP, PISP, PRSP, H.
influenzae, M. catarrhalis and marginal for K. pneumo-
niae, but not for P. aeruginosa.T h u s ,t h e4 0 0m gd o s ei s
not only ineffective but is also insufficient to prevent
resistance for P. aeruginosa.
We constructed a final population PK model from studies
of phase I trials, a clinical phase II trial of respiratory tract
infection (CAP, SICRD), and a clinical phase III study of
SICRD. Van Wart et al. [11] also developed a PK model of
garenoxacin from phase II studies of North America and
Europe for AECB, CAP, and sinusitis. Their PK model
included CLCR, ideal body weight, and extent of obesity as
covariates of CL/F, and body weight and gender as
covariates of V/F. Their covariates other than ideal body
weight and obesity extent were the same as our covariates
(Table 3). We selectedactualbodyweightinsteadofidealbody
weight and the obesity extent because the Japanese population
did not include highly obese subjects. In our population PK
analysis, the AUC and Cmax showed an inverse correlation
with body weight and renal function (Fig. 2). A standard PK
analysis by Krishna et al. [35] reported similar results in that
the the AUC in their patients with renal impairment not
requiring dialysis (CLCR<30 ml/min) was 51% higher than
that in normal subjects. The necessity of dose adjustment
for special populations is suggested by Fig. 2;f o r
example, 200 mg of garenoxacin given to a patient with
low body weight (<40 kg) or moderate to severe renal
impairment might be enough for adequate efficacy.
We chose SICRD, including AECB, as the investigating
targetdisease forthephaseIIIPK/PDstudy.Variouscausative
bacteria were observed, including non-susceptible and
susceptible bacteria (Table 2). We have identified that the
fAUC0−24/MIC ratio was a significant variable associated
with the clinical efficacy (Table 6;F i g .5). On the other hand,
a traditional controlled study compares a few doses of the
test drug with reference to the standard dose of a comparable
drug. The relationship between dose and clinical effect has
often been unclear in past studies because of bias in the
isolation frequencies of mixed sensitive and insensitive
bacteria. In contrast, the PK/PD analysis is able to find an
effective dose, stratified by each causative organism. This is
Table 7 Comparison between expectation by the Monte Carlo simulation and the observed results in the phase III study
Pathogens Monte Carlo simulation at the end of phase II stage Phase III study
fAUC0−24/MIC, h [median
(5–95% percentiles)]
Target attainment
a (%) Efficacy rate
b Bacterial eradication rate
c
MSSA 1097 (650–2225) 100 7/8 6/8
PSSP 690 (372–1454) 100 6/6 5/5
PISP, PRSP 774 (375–1482) 100 7/8 8/8
H. influenzae 3479 (1494–9259) 100 28/29 26/27
M. catarrhalis 1227 (231–4895) 100 6/7 6/6
K. pneumoniae 188 (4–493) 87 3/4 2/4
P. aeruginosa 11 (0–36) 6 2/5 1/5
a Probability that fAUC0−24/MIC exceeds 30 h
b Efficacy rate: patients who were cured / number of patients
c Bacterial eradication rate: patients with pathogen eradicated/number of patients with pathogen. Data were missing for four patients
Eur J Clin Pharmacol (2012) 68:39–53 51an advantage of the PK/PD method, and the results obtained
provide stronger scientific rationale. We implemented the
PK/PD method for dose selection of garenoxacin (in 2002
after completing the phase II trial) and confirmed the
recommended dose by a subsequent phase III trial (con-
ducted during 2002–2005). The comparison of the predicted
in silico efficacy against causative bacteria and the results of
the clinical trial is a novel learning–confirming method for
new drug development. We conducted the model-based drug
development throughout the clinical trials of garenoxacin in
Japan. This development strategy utilized a combination of
the PK/PD concept with the following rationalizations and
utility. (1) Certain optimal doses can be predicted early in the
drug development process. (2) The selected dose can be
confirmed by an appropriate open-label clinical PK/PD
study. (3) The altered PK of garenoxacin in a special
population, such as patients with renal impairment, can be
predicted from a population PK model. (4) Through this
adaptive approach the development period can be shortened
with a fewer number of trials and patients.
In practice, the PK/PD and Monte Carlo simulation
approach led us to use a smaller number of subjects (n=30
per group), whereas the conventional design usually requires
60 subjects per one group based upon the power calculations
for the phase II dose-finding study. An optimal dose could
not always be decided upon appropriately by the simple
comparison of efficacy rates in different doses. Thus, the risk
of failure was relatively high after proceeding to phase III
stage. The PK/PD design is advantageous for reducing the
time and cost of development by reducing the number of
subjects and can increase the success rate of drug develop-
ment because of the appropriately selected dose.
In conclusion, the optimal dose of garenoxacin for
patients with respiratory tract infection has been determined
to be 400 mg once daily by the prospective population PK/
PD analysis and clinical trial simulations.
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